CareDx, Inc.

Listed Company

CDNACIK 0001217234NasdaqLarge AcceleratedServices-Medical LaboratoriesDelawareFY ends Dec 31

Period

FY 2025

Revenue

$379.81M

Net Income

$-21.35M

Total Assets

$413.23M

Equity

$303.10M

Shares Out

51.66M

Op. Cash Flow

$42.03M

Business

CareDx, Inc. is a precision medicine company focused on the discovery, development and commercialization of clinically differentiated diagnostic solutions for transplant patients and caregivers. It offers diagnostic testing services, laboratory kit products, genomics-based information, patient support and digital solutions across the pre- and post-transplant journey, including AlloSure, AlloMap, AlloSeq, AlloCell and related offerings. The company operates as a single reportable segment organized around testing services, lab products and patient/digital solutions and also provides transplant-focused pharmacy services. It primarily serves transplant centers in the United States and Europe through regional sales teams, distributors and clinical laboratory channels.

Summary from filing dated 2025-02-28

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenue	380	334	280	322	296
Research and development	71	73	82	90	77
Sales and marketing	103	82	84	96	77
General and administrative	108	125	119	100	75
Litigation settlement expense	6	−96	96	—	—
Total operating expenses	411	293	484	399	326
(Loss) income from operations	−31	41	−203	−77	−30
Interest income, net	9	12	12	4	160,000
Other income, net	524,000	329,000	1	−3	−3
Total other income	10	12	13	997,000	−2
(Loss) income before income taxes	−21	53	−190	−76	−32
Income tax expense	−271,000	−310,000	−141,000	−379,000	1
Net (loss) income	−21	53	−190	−77	−31
Basic (in dollars per share)	−0.4	1	−3.54	−1.44	−0.59
Diluted (in dollars per share)	−0.4	0.93	−3.54	−1.44	−0.59
Basic (in shares)	53	53	54	53	52
Diluted (in shares)	53	57	54	53	52

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	65	115	82	90	348
Marketable securities	112	146	153	203	0
Accounts receivable	43	65	51	66	60
Inventory	27	20	19	19	17
Prepaid and other current assets	11	7	8	9	8
Total current assets	257	352	314	388	433
Property and equipment, net	33	34	35	36	22
Operating lease right-of-use assets	23	24	30	35	18
Marketable securities, non-current	24	0	—	—	—
Intangible assets, net	32	38	46	43	50
Goodwill	40	40	40	38	37
Restricted cash	600,000	585,000	586,000	522,000	211,000
Other assets	3	2	1	4	6
Total assets	413	491	467	543	567
Accounts payable	10	8	13	10	13
Accrued compensation	38	38	20	17	26
Accrued and other liabilities	42	43	45	49	38
Total current liabilities	90	89	78	76	77
Deferred tax liability	181,000	164,000	136,000	0	415,000
Contingent consideration	161,000	174,000	2	—	—
Operating lease liabilities, less current portion	20	22	28	33	17
Other liabilities	257,000	645,000	97	249,000	455,000
Total liabilities	110	113	205	112	101
Commitments and contingencies (Note 8)	—	—	—	—	—
Preferred stock: $0.001 par value; 10,000,000 shares authorized at December 31, 2025 and 2024; no shares issued and outstanding at December 31, 2025 and 2024	0	0	0	0	0
Common stock: $0.001 par value; 100,000,000 shares authorized at December 31, 2025 and 2024; 50,916,644 shares issued and outstanding at December 31, 2025; 54,771,203 shares issued and outstanding at December 31, 2024	50,000	51,000	49,000	52,000	52,000
Additional paid-in capital	1,044	1,013	947	899	854
Accumulated other comprehensive loss	−6	−9	−7	−8	−5
Accumulated deficit	−735	−626	−678	−460	−383
Total stockholders equity	303	378	261	431	466
Total liabilities and stockholders equity	413	491	467	543	567
Common stock, shares outstanding (in shares)	51	55	52	54	53
Common stock, shares issued (in shares)	51	55	52	54	53

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Stock-based compensation	35	66	49	47	36
Asset impairments and write-downs	0	0	1	—	—
Impairment of intangible asset and associated construction in progress	2	0	0	840,000	2
Depreciation and amortization	15	14	14	12	9
Amortization of right-of-use assets	5	6	5	4	3
Realized gain on sale of long-term marketable equity securities, net	0	0	−284,000	0	0
Loss on disposal of asset	48,000	91,000	44,000	0	0
Gain on settlement of obligation and recovery of written-off investment	0	0	−2	0	0
Revaluation of common stock warrant liability to estimated fair value	0	0	−10,000	−107,000	−106,000
Revaluation of contingent consideration to estimated fair value	703,000	931,000	3	727,000	−609,000
Amortization of premium and accretion of discount on marketable securities, net	1	621,000	−5	390,000	—
Accounts receivable	23	−14	16	−7	−24
Inventory	−5	−1	54,000	−3	−7
Prepaid and other assets	−4	606,000	2	−1	−5
Accounts payable	808,000	−5	3	−2	2
Accrued compensation	−845,000	19	3	−9	8
Accrued and other liabilities	−3	−96	90	11	11
Accrued royalties	0	0	−2	0	0
Operating lease liabilities, net	−6	−6	−5	−3	−3
Deferred taxes	17,000	−187,000	566,000	−215,000	−1
Net cash provided by (used in) operating activities	42	38	−18	−25	−19
Maturities of marketable securities	155	167	256	112	89
Purchases of marketable securities	−146	−160	−201	−315	−6
Purchase of corporate equity securities	0	−634,000	−965,000	0	0
Sale of corporate equity securities	0	0	2	0	0
Additions of capital expenditures	−6	−6	−8	−21	−14
Acquisition of intangible assets	−675,000	0	−896,000	−3	−7
Acquisition of business, net of cash acquired	0	0	−7	−610,000	−15
Net cash provided by (used in) investing activities	2	−483,000	40	−229	48
Payment of contingent consideration	−2	−5	−625,000	−3	0
Repurchase and retirement of common stock	−88	−522,000	−28	−642,000	0
Proceeds from exercise of warrants	0	0	4,000	0	4,000
Proceeds from exercise of stock options	6	9	120,000	2	13
Proceeds from issuance of common stock under employee stock purchase plan	2	1	1	2	2
Taxes paid related to net share settlement of restricted stock units	−12	−10	−3	−6	−18
Net cash used in financing activities	−93	−6	−30	−5	186
Effect of exchange rate changes on cash and cash equivalents	−90,000	532,000	−112,000	23,000	−303,000
Net (decrease) increase in cash, cash equivalents and restricted cash	−49	32	−8	−258	214
Cash paid for income taxes	284,000	317,000	738,000	392,000	14,000
Shares issued in lieu of payment	88,000	174,000	216,000	319,000	296,000
Operating lease right-of-use assets	3	195,000	607,000	22	6
Purchases of capital expenditures in accounts payable and accrued liabilities	3	633,000	647,000	1	4
Employee stock purchase plan shares included in accrued compensation	1	975,000	556,000	686,000	2
Contingent consideration	0	0	3	0	5

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro